On 21 September 2026 Akums Drugs & Pharmaceuticals announced DCGI approval for a triple-therapy combikit for adults with Helicobacter pylori infection.
The kit combines Vonoprazan 20 mg, a potassium-competitive acid blocker, with the antibiotics Clarithromycin 500 mg and Amoxicillin 1,000 mg, taken twice daily for 14 days.
H. pylori infects the stomach lining and is linked to chronic gastritis, peptic ulcer and gastric cancer.
Heads the Central Drugs Standard Control Organisation (CDSCO); approves new drugs and fixed-dose combinations
National drug regulator under the Ministry of Health and Family Welfare
Parent law under which CDSCO and the DCGI regulate the approval, import and manufacture of drugs in India
General Science > Human diseases and pathogens
Potassium-competitive acid blocker. It suppresses stomach acid by blocking the proton pump's potassium site.
Several medicines packed together as one course to improve adherence.